# Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults

> **NCT04177355** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 127 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** BG505 SOSIP.664 gp140
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** 3M-052-AF
- **BIOLOGICAL:** CpG 1018
- **BIOLOGICAL:** GLA-LSQ
- **BIOLOGICAL:** Alum (Aluminum Hydroxide Suspension)
- **BIOLOGICAL:** Trimer 4571

## Key facts

- **NCT ID:** NCT04177355
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-13
- **Primary completion:** 2024-11-04
- **Final completion:** 2024-11-04
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2025-09-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04177355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04177355, "Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04177355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*